

Icetrokinra acetate

Chemical Properties

CAS No. :

Formula:

Molecular Weight:

Storage: Keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	Icetrokinra (JNJ-77242113) acetate is a potent oral selective antagonist of the IL-23 receptor. It inhibits IL-23-induced STAT3 phosphorylation in peripheral blood mononuclear cells (PBMC) with an IC50 of 5.6 pM and reduces IFN- γ production in natural killer (NK) cells induced by IL-23, with an IC50 of 18.4 pM. Icetrokinra acetate demonstrates anti-inflammatory properties in a TNBS-induced rat colitis model and is applicable to research on psoriasis, psoriatic arthritis, and inflammatory bowel diseases.
Targets(IC50)	STAT,IFNAR
In vivo	Icetrokinra acetate, administered orally at doses ranging from 0.03 to 10 mg/kg once daily for 7 days, reduces the colon weight-to-length ratio and alleviates weight loss in rats with TNBS-induced colitis. In a rat skin inflammation model, Icetrokinra acetate at doses greater than 10 mg/kg, given orally twice daily for 3 days, inhibits the upregulation of IL-17A and IL-22 induced by IL-23.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481